|
|
|
March 26, 2007
Evalve's Percutaneous MitraClip™ Device Results in Significant Reverse Left Ventricular Remodeling
Evalve was incorporated in 1999 to design, develop, manufacture, and market innovative devices to enable percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. The company's present development and clinical efforts are focused on mitral valve repair. Below, EValve reports successful reduction of mitral regurgitation for up three years and significant reversal of left ventricular remodeling.
--------------------------------
Evalve, a privately held medical device company, today
announced data demonstrating that successful reduction
of mitral regurgitation (MR) can be maintained for up
to 36 months following treatment with the MitraClip device.
The results at 12 months also show significant reverse
left ventricular remodeling, indicating improved left
ventricular function.
"Percutaneous repair with the MitraClip device
is demonstrating its potential value as an alternative
to open-heart surgery for the treatment of mitral regurgitation
in selected patients and has shown encouraging midterm
durability," said Dr Feldman, EVEREST II Co-Principal
Investigator. "The EVEREST trial, the only trial
of its kind in the world, is now also studying the use
of the MitraClip device in patients at higher risk for
surgical mortality." "With over 200 MitraClip
devices implanted to date, we are gaining experience and
our ability to reduce mitral regurgitation is increasing.
The MitraClip device provides a minimally invasive option
to reduce mitral regurgitation that still allows the patient
to undergo a first surgical repair later if needed,"
added Donald Glower, M.D., professor of cardiovascular
surgery at Duke University Medical Center and Co-Principal
Investigator of EVEREST II.
Back to News
|
|
| |
